Article

Facile, efficient conjugation of a trifunctional lanthanide chelate to a peripheral benzodiazepine receptor ligand.

Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409, USA.
Organic Letters (impact factor: 5.86). 05/2002; 4(7):1075-8. pp.1075-8
Source: PubMed

ABSTRACT [reaction: see text] Receptor-mediated imaging and therapy of diseased tissue is rapidly gaining favor in the medical community. The synthesis and facile aqueous/organic coupling of a peripheral-type benzodiazepine receptor ligand to a cyclen-based fluorophore is described herein. The contrast agent QM-CTMC-PK11195, when chelated with lanthanides, produces bright luminescence and good MRI contrast and can potentially serve as an imaging and demarcation agent for certain types of cancers.

0 0
 · 
0 Bookmarks
 · 
24 Views
  • Source
    Article: Molecular Imaging of the Translocator Protein (TSPO) in a Pre-Clinical Model of Breast Cancer
    Shelby K. Wyatt, H. Charles Manning, Mingfeng Bai, Stephanie N. Bailey, Pascal Gallant, Guobin Ma, Laura McIntosh, Darryl J. Bornhop
    [show abstract] [hide abstract]
    ABSTRACT: PurposeTo quantitatively evaluate the utility of a translocator protein (TSPO)-targeted near-infrared (NIR) probe (NIR-conPK11195) for in vivo molecular imaging of TSPO in breast cancer. ProceduresNIR-conPK11195 uptake and TSPO-specificity were validated in TSPO-expressing human breast adenocarcinoma cells (MDA-MB-231). In vivo NIR-conPK11195 biodistribution and accumulation were quantitatively evaluated in athymic nude mice bearing MDA-MB-231 xenografts. ResultsFluorescence micrographs illustrated intracellular labeling of MDA-MB-231 cells by NIR-conPK11195. Quantitative uptake and competition assays demonstrated dose-dependent (p < 0.001) and TSPO-specific (p < 0.001) NIR-conPK11195 uptake. In vivo, NIR-conPK11195 preferentially labeled MDA-MB-231 tumors with an 11-fold (p < 0.001) and 7-fold (p < 0.001) contrast enhancement over normal tissue and unconjugated NIR dye, respectively. ConclusionsNIR-conPK11195 appears to be a promising TSPO-targeted molecular imaging agent for visualization and quantification of breast cancer cells in vivo. This research represents the first study to demonstrate the feasibility of TSPO imaging as an alternative breast cancer imaging approach. Key wordsPeripheral benzodiazepine receptor-Translocator protein-PK 11195-Molecular imaging-Breast cancer-MDA-MB-231-Diagnosis-Steroidogenesis-Prognosis-Staging
    Molecular Imaging & Biology 04/2012; 12(3):349-358. · 3.84 Impact Factor
  • Source
    Article: Preclinical molecular imaging of the translocator protein (TSPO) in a metastases model based on breast cancer xenografts propagated in the murine brain.
    Shelby K Wyatt, H Charles Manning, Mingfeng Bai, Moneeb Ehtesham, Khubaib Y Mapara, Reid C Thompson, Darryl J Bornhop
    [show abstract] [hide abstract]
    ABSTRACT: Previous studies have demonstrated the feasibility of translocator protein (TSPO) imaging to visualize and quantify human breast adenocarcinoma (MDA-MB-231) cells in vivo using a TSPO-targeted near-infrared (NIR) probe (NIR-conPK11195). This study aimed to extend the use of the TSPO-targeted probe to a more biologically relevant and clinically important tumor microenvironment as well as to assess our ability to longitudinally detect the presence and progression of breast cancer cells in the brain. The in vivo biodistribution and accumulation of NIR-conPK11195 and free (unconjugated) NIR dye were quantitatively evaluated in intracranial MDA-MB-231-bearing mice and non-tumor-bearing control mice longitudinally once a week from two to five weeks post-inoculation. The in vivo time-activity curves illustrate distinct clearance profiles for NIR-conPK11195 and free NIR dye, resulting in preferential accumulation of the TSPO-targeted probe in the intracranial tumor bearing hemisphere (TBH) with significant tumor contrast over normal muscle tissue (p < 0.005 at five weeks; p < 0.01 at four weeks). In addition, the TSPO-labeled TBHs demonstrated significant contrast over the TBHs of mice injected with free NIR dye (p < 0.001 at four and five weeks) as well as over the TSPO-labeled non-tumor-bearing hemispheres (NTBHs) of control mice (p < 0.005 at four and five weeks). Overall, TSPO-targeted molecular imaging appears useful for visualizing and quantifying breast cancer xenografts propagated in the murine brain and may assist in preclinical detection, diagnosis and monitoring of metastatic disease as well as drug discovery. Furthermore, these results indicate it should be possible to perform TSPO-imaging of breast cancer cells in the brain using radiolabeled TSPO-targeted agents, particularly in light of the fact that [11C]-labeled TSPO probes such as [11C]-PK 11195 have been successfully used to image gliomas in the clinic.
    Current Molecular Medicine 02/2012; 12(4):458-66. · 5.10 Impact Factor
  • Source
    Article: A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening.
    H Charles Manning, Sarah M Smith, Michelle Sexton, Sarah Haviland, Mingfeng Bai, Kristin Cederquist, Nephi Stella, Darryl J Bornhop
    [show abstract] [hide abstract]
    ABSTRACT: We developed a molecular imaging agent (MIA), a conjugable form of PK11195 (conPK11195) coupled to a lissamine dye (Liss-ConPK11195), which targets the peripheral benzodiazepine receptor (PBR). To determine that our compound specifically binds to this 18 kDa protein, primarily expressed on the mitochondria, we performed classic binding studies on live MDA-MB-231 breast cancer cells and measured fluorescence in cell fractions of C6 glioma cells. We found that conPK11195 conjugated to the fluorophore retained significant binding to its target. Here we demonstrate the utility of the agent for in vitro imaging of live cells by specific binding to the protein of interest.
    Bioconjugate Chemistry 05/2006; 17(3):735-40. · 4.93 Impact Factor

Show more

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

bright luminescence
 
certain types
 
contrast agent QM-CTMC-PK11195
 
demarcation agent
 
facile aqueous/organic coupling
 
herein
 
imaging
 
medical community
 
peripheral-type benzodiazepine receptor ligand
 
text] Receptor-mediated imaging